Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Parallel, Active-controlled, Non-inferiority, Phase III Multiple Center Clinical Trial to Compare the Efficacy and Safety of JP-1366 20 mg Versus Esomeprazole 40 mg in Patients With Erosive Esophagitis

NCT05443984 is registered in ClinicalTrials.gov with Onconic Therapeutics Inc. as lead sponsor.

NCT NCT05443984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05443984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Parallel, Active-controlled, Non-inferiority, Phase III Multiple Center Clinical Trial to Compare the Efficacy and Safety of JP-1366 20 mg Versus Esomeprazole 40 mg in Patients With Erosive Esophagitis
Lead sponsor
Onconic Therapeutics Inc.
Phase
Phase 3
Overall status
Completed
Start date
January 17, 2022
Completion date
January 5, 2023
Enrollment
300 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

erosive esophagitis